Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Using Metabolon's Cellular Metabolism Tool

NEW YORK (GenomeWeb News) – Metabolon said today that Pfizer’s Bioprocess R&D Group is using the firm’s metabolomics technology in analyzing cellular metabolism in the biopharmaceutical production process.
 
Pfizer will use the biochemical profiling technology, called mVision, to analyze samples from bioreactors, said Research Triangle Park, NC-based Metabolon. The tool will enable researchers to identify essential nutrients that are depleted and unearth toxic metabolites in the cells.
 
“By monitoring a large number of biochemicals in a bioreactor process, customers can quickly uncover areas for optimization,” John Ryals, president and CEO of Metablon, said in a statement.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.